In this article, we will explore the best growth stocks to invest in according to billionaires.

Infotech and biotech remain two of the clearer growth pockets because the underlying spending data is still expanding. In infotech, Gartner said worldwide IT spending is projected to reach $6.15 trillion in 2026, up 10.8% from 2025. Within that, data center systems are expected to rise 31.7% to $653.4 billion, software 14.7% to $1.43 trillion, and server spending 36.9% year over year, which places growth squarely in AI infrastructure and enterprise software rather than in slower device categories.

Biotech is standing in a different but still measurable growth phase. On the product side, the FDA said CDER approved 46 novel drugs in 2025, showing continued output in new therapies. On the capital side, IQVIA reported that biopharma funding increased for a second straight year and that clinical trial starts have returned to pre-pandemic levels, while EY said life sciences M&A reached $240 billion in 2025, up 81% in value from 2024.

The outlook, based on those same sources, is continued IT growth led by AI-linked spending and continued biotech activity supported by approvals, funding, trials, and dealmaking rather than by broad-based exuberance.

Methodology

We used screeners to narrow down to stocks with a forward revenue CAGR over 25%, and, among these, picked the ones that the highest number of billionaires were holding as of Q4, 2025. We then limited our selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among elite hedge funds and Wall Street analysts.

Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).

11. Guardant Health, Inc. (NASDAQ:GH)

Guardant Health, Inc. (NASDAQ:GH) is one of the best growth stocks to buy according to billionaires.

As of March 13, 2026, Guardant Health carried a Moderate Buy consensus from 23 analysts, based on 21 Buy ratings, one Hold, and one Sell. The average 12-month price target stood at $122.57, implying about 43% upside from the recent share price of $85.49, while the published target range ran from $55 to $180.

The bullish tone came after a stretch of company updates that gave analysts more to work with than a single earnings print. On February 19, 2026, Guardant Health reported fourth-quarter 2025 revenue of $281.3 million, up 39% year over year, with oncology revenue rising 30% to $189.9 million and screening revenue reaching $35.1 million. The company said it expects total 2026 revenue to grow 27% to 30%.

Management then added more detail at the Leerink Global Healthcare Conference on March 10, 2026, and the Barclays 28th Annual Global Healthcare Conference on March 11, 2026. At those events, Guardant highlighted its Quest Diagnostics partnership as a key commercial lever for Shield and said any upside from Quest’s co-promotion was not included in 2026 guidance. The company also said 90% of Shield users had not been screened in the prior five years, reinforcing its view that Shield can expand the screening market rather than just compete within it. Management also pointed to further portfolio catalysts, including potential FDA-related progress tied to ESR1 monitoring in Guardant360, while noting that Reveal Ultra was excluded from 2026 guidance because reimbursement remains uncertain.

Against that backdrop, Piper Sandler analyst David Westenberg maintained a Buy rating and $130 price target on March 11, 2026, after raising his target from $120 to $130 on February 24, 2026, following the company’s quarterly release.

Guardant Health, Inc. (NASDAQ:GH) is a precision oncology company that develops blood-based tests for cancer screening, treatment selection, and recurrence monitoring.

10. CoreWeave, Inc. (NASDAQ:CRWV)

CoreWeave, Inc. (NASDAQ:CRWV) is one of the best growth stocks to invest in according to billionaires.

As of March 13, CoreWeave carries a consensus analyst rating of “Moderate Buy” based on 32 Wall Street ratings, with 18 buy ratings, 12 hold ratings, and 2 sell ratings. The average 12-month price target sits at $122.35, implying about 50.9% upside from the referenced share price of $81.11. The stock has also drawn heavy analyst attention lately.

The backdrop was followed by Evercore ISI’s March 9, 2026, rating action on the stock. Evercore ISI analyst Amit Daryanani lowered the firm’s price target on CoreWeave to $120 from $150 while maintaining an Outperform rating. The publicly available summary said the revision followed a “deep dive into new project margin builds,” suggesting the firm remained constructive on the company’s positioning while taking a more measured view of project-level economics.

For context, CoreWeave has continued to announce projects and platform expansions. On March 10, the company introduced Flexible Capacity Plans, adding Flex Reservations and Spot offerings to its capacity framework for AI workloads. Earlier, on March 4, CoreWeave announced a strategic partnership with Perplexity to support the latter’s AI inference workloads on CoreWeave Cloud and to pilot new services across both organizations.

Moreover, in October, 2025, the company announced it would provide Poolside with a cluster of NVIDIA GB300 NVL72 systems, including more than 40,000 GPUs, while also planning to support Poolside’s Project Horizon campus in West Texas. The company also joined the Department of Energy’s Genesis Mission in December, expanding its role in public-sector and research-oriented AI infrastructure.

CoreWeave, Inc. (NASDAQ:CRWV) is an AI cloud infrastructure company that provides compute capacity, software tools, and related services designed for AI model training and inference. Founded in 2017, the company operates a purpose-built cloud platform for AI customers across enterprise, startup, and public-sector markets.